Amendment to the Amendment in the Nature of a Substitute to Subtitle J
Offered by Rep. LaHood of Illinois

The amendment would require that no provision of H.R. 3 shall result in a shift in investment of pharmaceutical biotechnology or drug manufacturing jobs from the U.S. to other foreign countries, including China. (Standing Up to China Act)
AMENDMENT TO THE AMENDMENT IN THE NATURE OF A SUBSTITUTE TO COMMITTEE PRINT FOR SUBTITLE J RELATING TO DRUG PRICING

OFFERED BY M. "La" Hood

Add at the end of section 139002 the following new subsection:

1. (f) Certification for Implementation.—Notwithstanding any preceding provision of, or amendment made by, this part, no such provision or amendment shall apply before the date on which the Secretary of Health and Human Services submits to Congress a certification that the implementation of such provisions or amendments will not result in a shift in investment of pharmaceutical biotechnology in the United States, or manufacturing jobs in the United States moving to China.

[Signature]

[Date]

[Place]